SUPPLEMENT TO DEFINITIVE PROXY STATEMENT RELATING TO
THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON OCTOBER 13, 2022
On August 22, 2022, KalVista Pharmaceuticals, Inc. (the “Company”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission, which was distributed in connection with the Company’s Annual Meeting of Stockholders scheduled for October 13, 2022 (the “Annual Meeting”). This supplement (this “Supplement”) updates and replaces the disclosure in the Proxy Statement under the heading “Security Ownership of Certain Beneficial Owners and Management” with current information as described below received by the Company. The information contained in this Supplement is incorporated by reference into the Proxy Statement. The Proxy Statement contains important information, and this Supplement should be read in conjunction with the Proxy Statement. Terms used in these additional definitive materials, but not otherwise defined, shall have the meanings ascribed to such terms in the Proxy Statement.
* * *
UPDATE TO SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table presents information as to the beneficial ownership of our common stock as of July 31, 2022 for:
| • | | each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; |
| • | | each NEO as set forth in the summary compensation table above; |
| • | | each of our directors; and |
| • | | all executive officers and directors as a group. |
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting and/or investment power with respect to securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table below have sole voting and sole investment power with respect to all shares beneficially owned, subject to community property laws where applicable. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of July 31, 2022 are deemed to be outstanding and to be beneficially owned by the person holding the options for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.
Percentage ownership of our common stock in the table is based on 24,570,872 shares of our common stock issued and outstanding on July 31, 2022. Unless otherwise indicated, the address of each of the individuals and entities named below is c/o KalVista Pharmaceuticals, Inc., 55 Cambridge Parkway, Suite 901E, Cambridge, Massachusetts 02142.
| | | | | | | | | | | | | | | | |
Name of Beneficial Owner | | Shares of Common Stock Beneficially Owned | |
| Common Stock | | | Securities Exercisable Within 60 Days | | | Number of Shares Beneficially Owned | | | Percent | |
Named Executive Officers and Directors: | | | | | | | | | | | | | | | | |
T. Andrew Crockett(1) | | | 108,170 | | | | 723,625 | | | | 831,795 | | | | 3.3 | % |
Benjamin L. Palleiko(2) | | | 65,000 | | | | 360,291 | | | | 425,291 | | | | 1.7 | % |
Christopher M. Yea, Ph.D.(3) | | | 32,969 | | | | 335,805 | | | | 368,774 | | | | 1.5 | % |
Albert Cha, M.D., Ph.D.(4) | | | 734,350 | | | | 48,166 | | | | 782,516 | | | | 3.2 | % |
Martin Edwards, M.D.(5) | | | — | | | | 30,166 | | | | 30,166 | | | | * | % |
Brian J. G. Pereira, M.D.(6) | | | — | | | | 30,166 | | | | 30,166 | | | | * | % |
Patrick Treanor(7) | | | — | | | | 1,888 | | | | 1,888 | | | | * | % |
Nancy Stuart(8) | | | — | | | | 7,000 | | | | 7,000 | | | | * | % |
Edward W. Unkart(9) | | | — | | | | 48,166 | | | | 48,166 | | | | * | % |
2